July 13, 2024 — Barely seven months ago, business reporters were telling us Pfizer had decided to “drop,” “stop,” “can,” or “pull the plug” on danuglipron – an oral small molecule for obesity. But as we pointed out at the time, they missed the real story. Pfizer was shifting its gears to focus on a once daily form of […]
December 2, 2023 — Dozens of new obesity medicines are in the pipeline for clinical development. Some folks are especially interested in oral medicines that are small molecules. They’re looking for something that offers a sharp contrast with the complex peptide molecules (like semaglutide) given by injection, which are expensive and hard to make. One of the small, orally […]
May 23, 2023 — A pair of reports on Monday raised the possibility that we may soon have oral obesity meds that match the remarkable effectiveness of injections. One of these drugs is an oral formulation of semaglutide that’s already available at a much lower oral dose for diabetes under the brand name of Rybelsus. Novo Nordisk makes it. […]
June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]
